Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

MicroRNAs play an important role in human cancer

Over the past few years, scientists have discovered that a new class of genetic regulators called "microRNAs" influences normal human growth and development. Now, researchers have found that microRNAs also play an important role in human cancer. The findings are published in today's issue of the journal Nature (June 9).

9 Jun 2005

New study shows tiny RNAs intimately associated with cancer

In discoveries that may open a new chapter in understanding and diagnosing cancer, Howard Hughes Medical Institute (HHMI) investigators and their colleagues have established that tiny microRNAs provide a novel genetic route to the initiation of some forms of cancer.

9 Jun 2005

Rituximab provides new hope for people with lupus

Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.

9 Jun 2005

Researchers link aberrant 'microRNA' expression to human cancer

8 Jun 2005

New understanding of microRNAs

Ribonucleic acid, or RNA, has long been thought to be important only to translate a gene's DNA into the proteins that are cells' workhorses. But new evidence shows that tiny bits of RNA not used to make proteins actually play central roles in normal biology and in the development of cancers.

8 Jun 2005

Drinking alcohol may lower risk of developing non-Hodgkin's lymphoma

People who drink alcohol may have a lower risk of developing non-Hodgkin's lymphoma (NHL) - a type of cancer that affects the lymphatic system, suggests a study published online by The Lancet Oncology.

6 Jun 2005

Emergence of cancer as a major cause of death among children in developing regions of the world is not being adequately addressed

This growing rate of pediatric cancer is occurring as the number of children dying from infectious diseases is being reduced through the efforts of the World Health Organization and international charities, the researchers say.

29 May 2005

Cyclophosphamide may be a possible therapy for scleroderma

A drug that suppresses the immune system and reduces inflammation has been shown to be effective in treating lung disease associated with the devastating connective tissue disease scleroderma, according to results presented at the American Thoracic Society International Conference on May 23.

24 May 2005

Findings demonstrate that abnormal expression of the BCL6 gene causes lymphoma

This advancement has the potential to significantly speed the development of new, improved therapies for diffuse large B cell lymphoma (DLBCL), the most common type of human B cell lymphoma. Human B cell lymphomas cause 85 percent of non-Hodgkin’s lymphomas, the sixth leading cause of cancer deaths in the United States.

23 May 2005

Long-term outcomes studied for stem cell transplant recipients

Improved techniques and supportive care have resulted in a growing number of long-term survivors of stem cell transplants, though little is known about the impact transplants have on patients’ lives long after treatment.

23 May 2005

Sunshine makes you feel good and may also help fight cancers

Although Vitamin D, the sunshine vitamin, gets little media attention, it is, surprisingly, a good tool in the fight against cancer.

22 May 2005

Antiretroviral therapy may prevent excess risk of some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active anti-retroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

18 May 2005

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Researchers at the Keck School of Medicine of the University of Southern California and colleagues have found a way to streamline a new form of treatment for patients with non-Hodgkin's lymphoma.

18 May 2005

Zevalin safe and effective for non-Hogdkin's lymphoma patients

According to a University of Pittsburgh Medical Center (UPMC) study, patients with advanced non-Hodgkin's lymphoma (NHL) previously treated with chemotherapy and adult stem cell transplantation can safely tolerate Zevalin (ibritumomab tiuxetan), a radiolabeled monoclonal antibody that targets radiation directly to a tumor.

17 May 2005

Tumor vasculature has become an attractive target in the treatment of cancer.

Treatment with a protein fused to an antibody in tumor-bearing mice led to coagulation of the blood within the tumor blood vessels, tumor tissue death, and tumor growth delay, according to a new study in the May 18 issue of the Journal of the National Cancer Institute.

17 May 2005

Researchers create the first mouse model that develops a lymphoma the same way that humans do

This advancement has the potential to significantly speed the development of new, improved therapies for diffuse large B cell lymphoma (DLBCL), the most common type of human B cell lymphoma. Human B cell lymphomas cause 85 percent of non-Hodgkin's lymphomas, the sixth leading cause of cancer deaths in the United States.

17 May 2005

Drugs that block the enzyme Odc prevent the onset of cancers

The drug DFMO prevents cancer in laboratory models of lymphoma but fails to kill existing cancerous cells that have lost the ability to self-destruct, according to investigators at St. Jude Children's Research Hospital.

16 May 2005

New predictor for blood transplant success

The success of blood stem cell transplants used to treat diseases such as leukemia, Hodgkin’s lymphoma and aplastic anemia may soon become more predictable, thanks to a discovery made by researchers at the University of British Columbia.

11 May 2005

Giving children access to drug clinical trials is crucial, clofarabine approval shows

The accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) demonstrates the importance of offering children rapid access to new treatments through clinical trials, according to investigators at St. Jude Children's Research Hospital. Refractory or relapsed ALL is a disease that resists treatment.

2 May 2005

Researchers determine mechanism of action of chemotherapy drug motexafin gadolinium

The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.

1 May 2005